3.16
Vyome Holdings Inc Borsa (HIND) Ultime notizie
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate - Yahoo Finance
What is the current Price Target and Forecast for Vyome Holdings, Inc. (HIND) - Zacks Investment Research
Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition - TipRanks
Vyome Holdings Signs Letter of Intent With Remus Capital Series B II - TradingView — Track All Markets
Vyome Holdingson Dec 17, Entered Binding L - 富途牛牛
Vyome Subsidiary LiveChain Signs LOI to Take Control of Humanyze Assets - citybiz
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company - Yahoo Finance
Pomichter Stanley D Iii Net Worth (2025) - GuruFocus
Mohanjit Jolly Net Worth (2025) - GuruFocus
Vyome inches towards US FDA approval to enter $1B worth malignant fungating wound market - BioSpectrum India
Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints - MSN
Check Out Vyome Holdings Inc (HIND)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval - BioSpace
Vyome stock soars after malodor treatment shows positive results - Investing.com
Vyome stock soars after malodor treatment shows positive results By Investing.com - Investing.com UK
Vyome reports positive final Phase 2 results for VT-1953, plans to advance into pivotal study for FDA approval - marketscreener.com
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
Vyome Holdings (HIND) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
JOLLY MOHANJIT Insider Trades - Nasdaq
Vyome Holdings, Inc. (HIND) Recent Insider Transactions - Yahoo! Finance Canada
Vyome Holdings, Inc. (HIND) recent insider transactions - Yahoo Finance UK
Vyome Holdings, Inc. (HIND) Profit Margin (Quarterly) - Zacks Investment Research
Vyome Holdings files prospectus related to resale of 610,185 shares of common stock by selling stockholders - marketscreener.com
Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling Stockholders - TradingView
Vyome Holdings Inc. Reports Post-Merger Financials - MSN
Vyome taps Dr. Bardia as senior medical advisor for wound treatment - Investing.com Nigeria
Vyome Appoints Dr. Aditya Bardia as Senior Medical Advisor - citybiz
Vyome taps Dr. Bardia as senior medical advisor for wound treatment By Investing.com - Investing.com South Africa
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program - Yahoo Finance
Earnings call transcript: Vyome Holdings Q3 2025 sees strategic advancements - Investing.com Nigeria
Vyome Therapeutics2025 Latest Shareholding - Tracxn
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing - Bluefield Daily Telegraph
Vyome Holdings Inc. (HIND) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vyome Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
HIND Forecast — Price Target — Prediction for 2026 - TradingView
Critical Contrast: Vyome (NASDAQ:HIND) vs. TranS1 (OTCMKTS:BAXSQ) - Defense World
Working capital per share of Vyome Holdings, Inc. – MUN:H1O - TradingView
ReShape Lifesciences (OTCMKTS:RSLSD) vs. Vyome (NASDAQ:HIND) Critical Analysis - Defense World
Vyome Holdings Announces Results of Annual Shareholder Meeting - The Joplin Globe
Contrasting ReShape Lifesciences (OTCMKTS:RSLSD) & Vyome (NASDAQ:HIND) - Defense World
Comparing Anzu Special Acquisition Corp I (NASDAQ:ANZUW) & Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Elects Directors at Annual Meeting - MSN
Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - Markets Financial Content
Head-To-Head Contrast: Vyome (NASDAQ:HIND) & TranS1 (OTCMKTS:BAXSQ) - Defense World
ReShape Lifesciences : trade; to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate UpdateForm 8-K/A - MarketScreener
Tincoff John M. Iii Net Worth (2025) - GuruFocus
ReShape Lifesciences (OTCMKTS:RSLSD) versus Vyome (NASDAQ:HIND) Financial Survey - Defense World
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):